PD1 monotherapy reigns supreme in adjuvant melanoma…but for how long?
Ryan C AugustinJason John LukePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The results of CheckMate-238 led to the original FDA approval of anti-PD1 therapy in high-risk, resectable melanoma. In this CCR Translations, we discuss the 5-year update of this pivotal trial and contextualize its results in the face of limited survival data, neoadjuvant therapy, next-generation biomarkers, and novel immunotherapy combinations.
Keyphrases
- locally advanced
- rectal cancer
- early stage
- clinical trial
- lymph node
- electronic health record
- study protocol
- squamous cell carcinoma
- dendritic cells
- regulatory t cells
- stem cells
- phase iii
- open label
- skin cancer
- immune response
- combination therapy
- bone marrow
- mesenchymal stem cells
- basal cell carcinoma
- replacement therapy